Tetraphase Pharmaceuticals Inc (TTPH) 35.18 $TTPH
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 04, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the following upcoming investor conferences:
TTPH: 35.18 (-0.73)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
Can the Uptrend Continue for Tetraphase Pharmaceuticals (TTPH)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:21AM CST
Can the Uptrend Continue for Tetraphase Pharmaceuticals (TTPH)?
TTPH: 35.18 (-0.73)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:10AM CST
Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from a phase III study evaluating its experimental antibiotic, eravacycline.
TTPH: 35.18 (-0.73), JNJ: 99.62 (+1.18), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 99.62 (+1.18), TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:47AM CST
NETE: 1.29 (+0.14), TTPH: 35.18 (-0.73), NES: 3.52 (+0.13), OVAS: 44.32 (+0.87), MCEP: 6.29 (+0.12), FMD: 5.45 (-0.16), ISIG: 3.19 (unch), WOR: 31.13 (+0.33), IMNP: 1.87 (-0.03), GLRI: 3.78 (+0.47), MBT: 10.36 (+0.62), NDRO: 4.94 (-0.02), OBCI: 4.95 (+0.32), INS: 2.10 (unch), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), MPO: 1.00 (-0.02), TRXC: 2.86 (-0.11), CRK: 6.09 (+0.46), ZAGG: 6.47 (+0.05)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Taking Wall Street by Storm: Special Coverage on Tetraphase, Oracle, Jabil, Paramount and Target
PR Newswire - Thu Dec 18, 8:28AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Tetraphase (NASDAQ: TTPH), Oracle (NYSE: ORCL), Jabil (NYSE: JBL), Paramount (NYSE MKT: PZG), and Target (NYSE: TGT). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TTPH: 35.18 (-0.73), PZG: 1.49 (+0.02), TGT: 76.12 (-0.75), JBL: 22.27 (+0.27), ORCL: 43.93 (+0.04)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST
VIP: 5.37 (+0.51), TTPH: 35.18 (-0.73), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), OVAS: 44.32 (+0.87), EOX: 1.15 (unch), NVGN: 2.79 (+0.17), WLT: 1.09 (+0.05), AKS: 4.87 (+0.39), MBT: 10.36 (+0.62), NADL: 2.10 (-0.02), NQ: 3.95 (-0.03), RVLT: 1.14 (-0.02), SSE: 5.23 (+0.22), AREX: 8.15 (+0.27), RAD: 8.34 (+0.25), AGEN: 5.03 (-0.01), PBR: 6.98 (+0.44), DNKN: 46.70 (-0.69), GDP: 3.58 (+0.29), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), LINE: 12.94 (+0.40)
Market Maker Surveillance Report. SFY, NES, GASL, MDBX, TTPH, XNCR, Winning Stocks With Lowest Price Friction For Wednesday, December 17th 2014
M2 - Thu Dec 18, 12:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4931 companies with "abnormal" market making, 4995 companies with positive Friction Factors and 2119 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Swift Energy Co (NYSE:SFY), M/S GBCPN 3 GBL INDS (NYSE:NES), Direxion Daily Natural Gas Related Bull 2x Shares (NYSE:GASL), (OTC:MDBX), (NASDAQ:TTPH), (NASDAQ:XNCR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
TTPH: 35.18 (-0.73), GASL: 4.37 (+0.39), NES: 3.52 (+0.13), SFY: 2.91 (+0.26), XNCR: 15.47 (-0.22)
TETRAPHASE PHARMA
at Investor's Business Daily - Wed Dec 17, 5:50PM CST
TETRAPHASE PHARMA (TTPH) rose 14.5% to 37.99 after unveiling positive phase 3 trial results on eravacycline for treating intra-abdominal infections. The developer of antibiotics for resistant infections had closed up 10.6% to 33.19, a new high.
TTPH: 35.18 (-0.73)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 4:40PM CST
E: 36.31 (+0.69), TTPH: 35.18 (-0.73), RCAP: 10.28 (+0.28), PKD: 3.50 (+0.18), RUSS: 11.59 (-0.81), GTI: 4.16 (+0.32), AKS: 4.87 (+0.39), REI: 10.00 (+0.27), ORCL: 43.93 (+0.04), ZAGG: 6.47 (+0.05)
Tetraphase antibiotic non-inferior to ertapenem in Phase 3 study
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:44PM CST
TTPH: 35.18 (-0.73)
Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
Business Wire - Wed Dec 17, 3:01PM CST
----Company to host conference call at 4:30 p.m. ET today -
TTPH: 35.18 (-0.73)
3 Momentum Stocks Undeterred by a Shaky Market - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Dec 16, 10:04AM CST
These stocks look to be a great play when the market has been trapped in the vicious circle of oil trading.
PTRY: 36.72 (+0.05), TTPH: 35.18 (-0.73), BBW: 20.94 (+0.14)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:18AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Tetraphase Fights Drug-Resistant Bugs As M&A Heats Up
at Investor's Business Daily - Mon Feb 09, 3:53PM CST
One lesson to draw from recent M&A in the pharma space: Superbug drugs are hot. Last year, Actavis (ACT) plunked down $675 million for Durata Therapeutics, whose drug Dalvance fights some of the nastiest specimens of the class known as gram-positive...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), MDCO: 29.79 (+0.91), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07)
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Feb 04, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the following upcoming investor conferences:
TTPH: 35.18 (-0.73)
Product and Pipeline Analysis of the Antibacterial Drugs Market 2015
M2 - Sat Jan 31, 12:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/knzdss/a_product_and) has announced the addition of the "A Product and Pipeline Analysis of the Antibacterial Drugs Market " report to their offering. Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well. Antibacterial Drugs Listed - Tedizolid Phosphate-Cubist Pharmaceuticals - Dalbavancin (Dalvance)-Durata Therapeutics - Ceftolozane Tazobactam-Cubist Pharmaceuticals - Oritavancin (Orbactiv)-The Medicines Company - Ceftazidime Avibactam (CAZ-AVI)-AstraZeneca - Cadazolid-Actelion Pharmaceuticals - Carbavance-Rempex Pharmaceuticals (The Medicines Company) - Delafloxacin-Melinta Therapeutics - Eravacycline-Tetraphase Pharmaceuticals - Plazomicin-Achaogen - Solithromycin-Cempra Pharmaceuticals - Surotomycin-Cubist Pharmaceuticals Key Topics Covered: 1. Executive Summary 2. Introduction 3. Classification Of Antibacterial Drugs By Mechanism Of Action 4. Antibacterial Drugs Market-Pipeline Analysis 5. Antibacterial Drugs Market-Major Clinical Milestones 6. Antibacterial Drugs Market-Product Dashboard Of Recently Approved And Late-Stage Pipeline Drug Candidates 7. Antibiotic Resistance-A Critical Unmet Need That Poses Challenges To Antibiotic R&D 8. Antibacterial Drugs Market-Timeline Of Key Events 9. Regulatory Approaches To Stimulate Antibiotics R&D 10. Antibacterial Drugs Market-Key Companies To Watch 11. Conclusions 12. Appendix Companies Mentioned - Achaogen - Actelion Pharmaceuticals - AstraZeneca - Cempra Pharmaceuticals - Cubist Pharmaceuticals - Durata Therapeutics - Melinta Therapeutics - Rempex Pharmaceuticals - Tetraphase Pharmaceuticals - The Medicines Company For more information visit http://www.researchandmarkets.com/research/kn...roduct_and
DRTX: 24.16 (+0.41), TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), MDCO: 29.79 (+0.91)
Can the Uptrend Continue for Tetraphase Pharmaceuticals (TTPH)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 6:21AM CST
Can the Uptrend Continue for Tetraphase Pharmaceuticals (TTPH)?
TTPH: 35.18 (-0.73)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:10AM CST
Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from a phase III study evaluating its experimental antibiotic, eravacycline.
TTPH: 35.18 (-0.73), JNJ: 99.62 (+1.18), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:19PM CST
Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the treatment of complicated intra-abdominal infection.
JNJ: 99.62 (+1.18), TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:47AM CST
NETE: 1.29 (+0.14), TTPH: 35.18 (-0.73), NES: 3.52 (+0.13), OVAS: 44.32 (+0.87), MCEP: 6.29 (+0.12), FMD: 5.45 (-0.16), ISIG: 3.19 (unch), WOR: 31.13 (+0.33), IMNP: 1.87 (-0.03), GLRI: 3.78 (+0.47), MBT: 10.36 (+0.62), NDRO: 4.94 (-0.02), OBCI: 4.95 (+0.32), INS: 2.10 (unch), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), MPO: 1.00 (-0.02), TRXC: 2.86 (-0.11), CRK: 6.09 (+0.46), ZAGG: 6.47 (+0.05)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 35.18 (-0.73), ACT: 285.37 (+3.71), CBST: 101.94 (+0.14), MRK: 58.81 (-0.07)
Taking Wall Street by Storm: Special Coverage on Tetraphase, Oracle, Jabil, Paramount and Target
PR Newswire - Thu Dec 18, 8:28AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Tetraphase (NASDAQ: TTPH), Oracle (NYSE: ORCL), Jabil (NYSE: JBL), Paramount (NYSE MKT: PZG), and Target (NYSE: TGT). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
TTPH: 35.18 (-0.73), PZG: 1.49 (+0.02), TGT: 76.12 (-0.75), JBL: 22.27 (+0.27), ORCL: 43.93 (+0.04)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST
VIP: 5.37 (+0.51), TTPH: 35.18 (-0.73), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), OVAS: 44.32 (+0.87), EOX: 1.15 (unch), NVGN: 2.79 (+0.17), WLT: 1.09 (+0.05), AKS: 4.87 (+0.39), MBT: 10.36 (+0.62), NADL: 2.10 (-0.02), NQ: 3.95 (-0.03), RVLT: 1.14 (-0.02), SSE: 5.23 (+0.22), AREX: 8.15 (+0.27), RAD: 8.34 (+0.25), AGEN: 5.03 (-0.01), PBR: 6.98 (+0.44), DNKN: 46.70 (-0.69), GDP: 3.58 (+0.29), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), LINE: 12.94 (+0.40)
Market Maker Surveillance Report. SFY, NES, GASL, MDBX, TTPH, XNCR, Winning Stocks With Lowest Price Friction For Wednesday, December 17th 2014
M2 - Thu Dec 18, 12:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4931 companies with "abnormal" market making, 4995 companies with positive Friction Factors and 2119 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Swift Energy Co (NYSE:SFY), M/S GBCPN 3 GBL INDS (NYSE:NES), Direxion Daily Natural Gas Related Bull 2x Shares (NYSE:GASL), (OTC:MDBX), (NASDAQ:TTPH), (NASDAQ:XNCR). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
TTPH: 35.18 (-0.73), GASL: 4.37 (+0.39), NES: 3.52 (+0.13), SFY: 2.91 (+0.26), XNCR: 15.47 (-0.22)
TETRAPHASE PHARMA
at Investor's Business Daily - Wed Dec 17, 5:50PM CST
TETRAPHASE PHARMA (TTPH) rose 14.5% to 37.99 after unveiling positive phase 3 trial results on eravacycline for treating intra-abdominal infections. The developer of antibiotics for resistant infections had closed up 10.6% to 33.19, a new high.
TTPH: 35.18 (-0.73)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 4:40PM CST
E: 36.31 (+0.69), TTPH: 35.18 (-0.73), RCAP: 10.28 (+0.28), PKD: 3.50 (+0.18), RUSS: 11.59 (-0.81), GTI: 4.16 (+0.32), AKS: 4.87 (+0.39), REI: 10.00 (+0.27), ORCL: 43.93 (+0.04), ZAGG: 6.47 (+0.05)
Tetraphase antibiotic non-inferior to ertapenem in Phase 3 study
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 3:44PM CST
TTPH: 35.18 (-0.73)
Tetraphase Announces Positive Top-line Results from Phase 3 IGNITE 1 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
Business Wire - Wed Dec 17, 3:01PM CST
----Company to host conference call at 4:30 p.m. ET today -
TTPH: 35.18 (-0.73)
3 Momentum Stocks Undeterred by a Shaky Market - Analyst Blog
Sweta Killa - Zacks Investment Research - Tue Dec 16, 10:04AM CST
These stocks look to be a great play when the market has been trapped in the vicious circle of oil trading.
PTRY: 36.72 (+0.05), TTPH: 35.18 (-0.73), BBW: 20.94 (+0.14)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:18AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
